Your Microbiome Is a Pharmacy
The human gut microbiome encodes over 3 million unique genes — roughly 150 times the human genome — and many of these genes encode enzymes capable of metabolising pharmaceutical drugs. This means that your medications encounter a vast, variable enzymatic factory before and after absorption, and the composition of your personal microbiome can significantly influence drug efficacy, toxicity, and side effects.
Known Drug-Microbiome Interactions
The most well-established example involves cardiac glycosides. Digoxin, a heart failure medication, is inactivated by Eggerthella lenta — a gut bacterium that reduces digoxin's lactone ring. Patients with high E. lenta abundance require higher doses to achieve therapeutic levels. Dietary arginine can inhibit E. lenta's digoxin-inactivating enzyme, adding another variable.
Sulphasalazine, used in IBD and rheumatoid arthritis, is a prodrug that requires bacterial azoreductase enzymes to cleave its azo bond, releasing the active anti-inflammatory component 5-aminosalicylic acid (5-ASA). Without adequate gut bacterial activity, the drug is ineffective.
Irinotecan, a chemotherapy agent for colorectal cancer, is a dramatic example of harmful microbiome-drug interaction. After hepatic metabolism, the inactive glucuronidated metabolite is excreted into the gut, where bacterial β-glucuronidase enzymes reactivate it — causing severe, dose-limiting diarrhoea. Efforts to co-administer bacterial β-glucuronidase inhibitors are under investigation.
Metformin, the first-line diabetes drug, has been shown to reshape the gut microbiome — increasing Akkermansia muciniphila and SCFA-producing bacteria. A significant portion of metformin's glucose-lowering effect may be mediated through the microbiome rather than through direct pharmacological action. The GI side effects (bloating, diarrhoea) that cause up to 30 percent of patients to discontinue metformin are also likely microbiome-mediated.
Scope of the Problem
A 2019 Nature study screened 76 gut bacterial strains against 271 commonly prescribed drugs and found that 176 drugs (65 percent) were significantly metabolised by at least one strain. This suggests that microbiome-mediated drug metabolism is the rule, not the exception — yet it is rarely considered in current prescribing practice.
Future Implications
Pharmacomicrobiomics points toward personalised prescribing: adjusting drug choice, dose, or co-therapy based on a patient's microbiome composition. Microbiome profiling before chemotherapy could predict toxicity risk. Identifying patients with high E. lenta burden could guide digoxin dosing. Engineering bacteria to deliver drugs site-specifically in the gut is an active area of synthetic biology research. While routine pharmacomicrobiomic profiling is not yet clinically available, the direction of travel is clear.